CoChat

What's the deal with niacin development: is laropiprant add-on therapy a winning strategy to beat a straight flush?

Bays, Harold E, Ballantyne, Christie · 2009 · Current Opinion in Lipidology

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Abstract

PURPOSE OF REVIEW: Niacin is a B-complex vitamin used as a lipid-altering drug since the 1950s. Niacin improves multiple lipid parameters. Atherosclerotic coronary heart disease outcome studies support niacin's efficacy in reducing coronary heart disease events, either as monotherapy or when used in combination with other lipid-altering drugs. The most commonly reported reason for the lack of its more widespread clinical use is niacin-induced flushing. RECENT FINDINGS: Laropiprant is a highly selective prostaglandin D2 receptor 1 antagonist that mitigates niacin-induced flushing. SUMMARY: This review examines the history and provides a perspective regarding the extended-release niacin/laropiprant development program, which was designed to better allow patients to achieve a more therapeutic niacin dose of 2 g/day, without the need for titration. Ongoing coronary heart disease outcome studies will provide better insight as to the benefits of niacin in general, and the safety and efficacy of extended-release niacin/laropiprant specifically.

Overview

Integrity signals

Registry

Crossref · 10.1097/mol.0b013e3283325083

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Cited by

See all 29

Metadata

Authors
Bays, H. E., & Ballantyne, C.
Affiliations
  • Louisville Metabolic and Atherosclerosis Research Center (US)
  • Baylor College of Medicine (US)
Corresponding author
Bays, Harold E
Venue
Current Opinion in Lipidology
Published
2009-12
Volume
20
Issue
6
Pages
467-476
ISSN
0957-9672 (ISSN-L)
OpenAlex
W2068615855
Cited by
29
References
42
Citations by year
2022: 1 · 2016: 1 · 2015: 1 · 2014: 4 · 2013: 2 · 2012: 7
FWCI
1.06
Type
journal article
Language
en
Open access
closed
Locations
  • Current Opinion in Lipidology (publishedVersion)
  • PubMed (publishedVersion)
Funders
Merck
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Nursing › Nutrition and Dietetics › Folate and B Vitamins Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Keywords
nicotinic acid, laropiprant, lipid-lowering therapy, coronary artery disease, hypercholesterolemia, drug development, dose titration
MeSH terms
Hypolipidemic Agents, Coronary Disease, Delayed-Action Preparations, Drug Combinations, Flushing, Humans, Indoles, Lipids, Niacin, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.